↓ Skip to main content

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

Overview of attention for article published in Lancet Oncology, February 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Readers on

mendeley
583 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 178 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 583 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 583 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 56 10%
Other 47 8%
Student > Ph. D. Student 44 8%
Student > Bachelor 39 7%
Student > Master 34 6%
Other 89 15%
Unknown 274 47%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 151 26%
Biochemistry, Genetics and Molecular Biology 37 6%
Pharmacology, Toxicology and Pharmaceutical Science 22 4%
Agricultural and Biological Sciences 20 3%
Immunology and Microbiology 11 2%
Other 51 9%
Unknown 291 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 222. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2026.
All research outputs
#220,276
of 34,764,228 outputs
Outputs from Lancet Oncology
#246
of 8,039 outputs
Outputs of similar age
#4,987
of 415,829 outputs
Outputs of similar age from Lancet Oncology
#8
of 117 outputs
Altmetric has tracked 34,764,228 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,039 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.5. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 415,829 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 117 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.